SGI-110 in Combination With Carboplatin in Ovarian Cancer
Public ClinicalTrials.gov record NCT01696032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer
Study identification
- NCT ID
- NCT01696032
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- SGI-110 Drug
- Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) Drug
- Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2012
- Primary completion
- Jul 31, 2016
- Completion
- Jul 31, 2016
- Last update posted
- Aug 26, 2024
2012 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Norris Comprehensive Cancer Center- University of Southern California | Los Angeles | California | 90033 | — |
| University of Florida Shands Cancer Center | Gainesville | Florida | 32610 | — |
| Georgia Health Sciences University | Augusta | Georgia | 30912 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Melvin and Bren Simon Cancer Center- Indiana University | Indianapolis | Indiana | 46202 | — |
| Women's Cancer Care | Covington | Louisiana | 70433 | — |
| Johns Hopkins Kimmel Cancer Center | Baltimore | Maryland | 21231 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Island Gynecologic Oncology | Brightwaters | New York | 11718 | — |
| Duke Cancer Institute- Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45267 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75201 | — |
| Inova Fairfax Hospital | Falls Church | Virginia | 22042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01696032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01696032 live on ClinicalTrials.gov.